@article{10902/27784,
year = {2022},
url = {https://hdl.handle.net/10902/27784},
abstract = {Background: The long-term cardiovascular (CV) outcomes of COVID-19 have not been fully explored.

Methods: This was an international, multicenter, retrospective cohort study conducted between February and December 2020. Consecutive patients ≥18 years who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 were included. Patients were classified into two cohorts depending on the nasopharyngeal swab result and clinical status: confirmed COVID-19 (positive RT-PCR) and control (without suggestive symptoms and negative RT-PCR). Data were obtained from electronic records, and clinical follow-up was performed at 1-year. The primary outcome was CV death at 1-year. Secondary outcomes included arterial thrombotic events (ATE), venous thromboembolism (VTE), and serious cardiac arrhythmias. An independent clinical event committee adjudicated events. A Cox proportional hazards model adjusted for all baseline characteristics was used for comparing outcomes between groups. A prespecified landmark analysis was performed to assess events during the post-acute phase (31-365 days).

Results: A total of 4,427 patients were included: 3,578 (80.8%) in the COVID-19 and 849 (19.2%) control cohorts. At one year, there were no significant differences in the primary endpoint of CV death between the COVID-19 and control cohorts (1.4% vs. 0.8%; HRadj 1.28 [0.56-2.91]; p = 0.555), but there was a higher risk of all-cause death (17.8% vs. 4.0%; HRadj 2.82 [1.99-4.0]; p = 0.001). COVID-19 cohort had higher rates of ATE (2.5% vs. 0.8%, HRadj 2.26 [1.02-4.99]; p = 0.044), VTE (3.7% vs. 0.4%, HRadj 9.33 [2.93-29.70]; p = 0.001), and serious cardiac arrhythmias (2.5% vs. 0.6%, HRadj 3.37 [1.35-8.46]; p = 0.010). During the post-acute phase, there were no significant differences in CV death (0.6% vs. 0.7%; HRadj 0.67 [0.25-1.80]; p = 0.425), but there was a higher risk of deep vein thrombosis (0.6% vs. 0.0%; p = 0.028). Re-hospitalization rate was lower in the COVID-19 cohort compared to the control cohort (13.9% vs. 20.6%; p = 0.001).

Conclusions: At 1-year, patients with COVID-19 experienced an increased risk of all-cause death and adverse CV events, including ATE, VTE, and serious cardiac arrhythmias, but not CV death.},
organization = {Funding: This research was funded by Carlos III Health Institute (Madrid, Spain) and co-funded by the European Union, grant number COV20/00040. Dr. Bikdeli is supported by the Scott Schoen and Nancy Adams IGNITE Award from the Mary Horrigan Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital and a Career Development Award from the American Heart Association (#938814).},
publisher = {Public Library of Science},
publisher = {PLoS One
, 2022, 17(12), e0279333},
title = {One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry},
author = {Ortega-Paz, Luis and Arévalos, Victor and Fernández-Rodríguez, Diego and Jiménez-Díaz, Víctor and Bañeras, Jordi and Campo, Gianluca and Rodríguez-Santamarta, Miguel and Díaz, José Francisco and Scardino, Claudia and Gómez-Álvarez, Zaira and Pernigotti, Alberto and Alfonso, Fernando and Amat-Santos, Ignacio J and Silvestro, Antonio and Rampa, Lorenzo and Torre Hernández, José María de la and Bastidas, Gabriela and Gómez-Lara, Josep and Bikdeli, Behnood and García-García, Hector M},
}